Peter Kim

Peter Kim, M.D., is the Director of the Therapeutics Research Program (TRP) at the Division of AIDS, National Institute of Allergy and Infectious Diseases. In conjunction with the many dedicated scientists in TRP, Dr. Kim oversees a broad portfolio of research grants and contracts to advance diagnostics and therapeutics for HIV, tuberculosis, and other HIV related co-infections.  His primary areas of expertise and interest include clinical TB and HIV drug development and treatment strategies, as well as TB biomarkers and diagnostics.   As part of the U.S. NIH research response to the COVID-19 Pandemic, Dr. Kim also leads the ACTIV-2 family of trials, which are dedicated to developing new outpatient, anti-viral treatments for early COVID-19.

Prior to becoming the Director of TRP, Dr. Kim served as the Deputy Director of the NIH Office of AIDS Research (OAR) which oversees the multi-billion dollar trans-NIH HIV research portfolio and budget.  

He is a U.S. Board certified Infectious Diseases specialist.  He received his bachelors degree in Public Health from the Johns Hopkins University, and his medical degree from the University of Maryland School of Medicine.  From there he went on to complete his training in Internal Medicine and Infectious Diseases at the Washington Hospital Center, in Washington, D.C..